Envestnet Asset Management Inc. Decreases Stock Position in PROCEPT BioRobotics Corporation $PRCT

Envestnet Asset Management Inc. decreased its position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 18.1% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 30,511 shares of the company’s stock after selling 6,762 shares during the period. Envestnet Asset Management Inc.’s holdings in PROCEPT BioRobotics were worth $1,757,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Osterweis Capital Management Inc. grew its stake in shares of PROCEPT BioRobotics by 98.0% during the first quarter. Osterweis Capital Management Inc. now owns 173,735 shares of the company’s stock valued at $10,122,000 after acquiring an additional 85,990 shares in the last quarter. Millennium Management LLC boosted its holdings in PROCEPT BioRobotics by 88.6% in the first quarter. Millennium Management LLC now owns 542,987 shares of the company’s stock valued at $31,634,000 after purchasing an additional 255,140 shares during the last quarter. Blair William & Co. IL boosted its holdings in PROCEPT BioRobotics by 5.7% in the second quarter. Blair William & Co. IL now owns 497,205 shares of the company’s stock valued at $28,639,000 after purchasing an additional 26,919 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new stake in PROCEPT BioRobotics during the 1st quarter valued at approximately $2,913,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in PROCEPT BioRobotics by 7.4% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,426 shares of the company’s stock worth $543,000 after purchasing an additional 647 shares during the last quarter. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Trading Down 2.3%

Shares of NASDAQ PRCT opened at $28.40 on Wednesday. PROCEPT BioRobotics Corporation has a 12-month low of $28.28 and a 12-month high of $100.89. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -18.56 and a beta of 0.98. The company has a current ratio of 8.44, a quick ratio of 7.20 and a debt-to-equity ratio of 0.14. The stock’s 50 day simple moving average is $34.74 and its 200 day simple moving average is $46.39.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. The firm had revenue of $83.33 million during the quarter, compared to the consensus estimate of $80.78 million. PROCEPT BioRobotics had a negative return on equity of 21.72% and a negative net margin of 28.20%.The firm’s revenue was up 42.6% on a year-over-year basis. During the same period in the prior year, the business earned ($0.40) EPS. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts expect that PROCEPT BioRobotics Corporation will post -1.75 EPS for the current year.

Wall Street Analyst Weigh In

PRCT has been the subject of several research analyst reports. TD Cowen reduced their target price on PROCEPT BioRobotics from $85.00 to $50.00 and set a “buy” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PROCEPT BioRobotics in a report on Wednesday, October 8th. Piper Sandler reissued an “overweight” rating and set a $50.00 price objective (down from $55.00) on shares of PROCEPT BioRobotics in a report on Wednesday, November 5th. Wall Street Zen downgraded shares of PROCEPT BioRobotics from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Finally, Wells Fargo & Company reduced their price target on shares of PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $59.78.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).